3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Esophageal Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
pembrolizumab
32
Cisplatin
10
Paclitaxel
8
lenvatinib
6
belzutifan
5
Carboplatin
5
Saline Solution
4
Oxaliplatin
4
Fluorouracil
4
Pemetrexed
3
Leucovorin
3
Etoposide
3
Docetaxel
3
olaparib
2
enfortumab vedotin
2
durvalumab
2
Radiotherapy
2
Levoleucovorin
2
Glucose
2
Capecitabine
2
Bevacizumab
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
tislelizumab
1
sacituzumab govitecan
1
liposomal doxorubicin
1
enzalutamide
1
balstilimab
1
avelumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
zanidatamab
×
Clear all
NCT05152147
2026-05-19
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3
Active not recruiting
920 enrolled